Ссылки

1.Bjelakovic G., Nikolova D., Gluud L. L., et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2008; 2: CD007176.

2.Knaus H. Corporate profi le, Ciba Geigy: pushing pills and pesticides. Multinational Monitor. 1993. Available online at: http://multinationalmonitor.org/hyper/issues/1993/04/mm0493_11.html (accessed 10 July 2012).

3.Dunne M., Flood M., Herxheimer A. Clioquinol: availability and instructions for use. J. Antimicrob Chemother. 1976; 2: 21–9.

4.Hansson O. Arzneimittel-Multis und der SMON-Skandal. Berlin: Arzneimittel-Informations-Dienst GmbH; 1979.

5.Hench P. S., Kendall E. C., Slocumb C. H., et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin. 1949; 24: 181–97.

6.Pearce N. Adverse Reactions: the fenoterol story. Auckland: Auckland University Press; 2007.

7.Gøtzsche P. C. Mammography Screening: truth, lies and controversy. London: Radcliffe Publishing; 2012.

8.Michaels D. Doubt is their Product. Oxford: Oxford University Press; 2008.

9.Smith S. M., Schroeder K., Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev. 2008; 1: CD001831.

10.Tomerak A. A. T., Vyas H. H. V., Lakhanpaul M., et al. Inhaled beta2-agonists for non-specific chronic cough in children. Cochrane Database Syst Rev. 2005; 3: CD005373.

11.Wilkinson E. A. J., Hawke C. C. Oral zinc for arterial and venous leg ulcers. Cochrane Database Syst Rev. 1998; 4: CD001273 (updated in 2010).

12.Husain S. L. Oral zinc sulphate in leg ulcers. Lancet. 1969; 1: 1069–

71.

13.Andersen L. A., Gøtzsche P. C. Naproxen and aspirin in acute musculoskeletal disorders: a doubleblind, parallel study in sportsmen. Pharmatherapeutica. 1984; 3: 535–41.

14.Jørgensen F. R., Gøtzsche P. C., Hein P, et al. [Naproxen (Naprosyn) and mobilization in the treatment of acute ankle sprains]. Ugeskr Læger. 1986; 148: 1266–8.

15.Allen C., Glasziou P., Del Mar C. Bed rest: a potentially harmful treatment needing more careful evaluation. Lancet. 1999; 354: 1229–33.

16.Gøtzsche P. C. Bias in double-blind trials. Dan Med Bull. 1990; 37:

329–36.

17.Gøtzsche P. C. Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials. J Clin Epidemiol. 1990; 43: 1313–18.

18.Gøtzsche P. C. Review of dose-response studies of NSAIDs in rheumatoid arthritis. Dan Med Bull. 1989; 36: 395–9.

19.Lopez B. L., Flenders P., Davis-Moon L. Clinically signifi cant differences in the visual analog pain scale in acute vasoocclusive sickle cell crisis. Hemoglobin. 2007; 31: 427–32.

20.Gøtzsche P. C. Non-steroidal anti-infl ammatory drugs. Clinical Evidence. 2004; 12: 1702–10.

21.Rost P. The Whistleblower: confessions of a healthcare hitman. New York: Soft Skull Press; 2006.

22.Abraham J. Science, Politics and the Pharmaceutical Industry. London: UCL Press; 1995.

23.Henry D., Lim L. L., Garcia Rodriguez L. A., et al. Variability in risk of gastrointestinal complications with individual non-steroidal antiinflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996;

312:1563–6.

24.Virapen J. Side Effects: death. College Station: Virtualbookworm.com Publishing; 2010.

25.Joyce C., Lesser F. Opren deaths kept secret, admits Lilly. New Sci. 1985; 107: 15–16.

26.Cotter J. New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). CMAJ. 2005; 172: 1299.